Articles tagged with Schizophrenia
The study found sex differences in age at diagnosis, treatment onset, illness duration, illicit drug use, and smoking among individuals with bipolar disorder and schizophrenia. Females showed better functioning and neurocognitive performance than males, while males had higher rates of substance use.
People with schizophrenia are more likely to develop chronic obstructive pulmonary disease (COPD) due to shared genetic, socioeconomic, and environmental factors. The lack of adequate medical care also contributes to the under-diagnosis of COPD in this population.
Newron Pharmaceuticals' evenamide has been shown to target the key site of schizophrenia pathology in the hippocampus, improving positive, negative, and cognitive symptoms. The study's findings suggest that evenamide could offer a novel therapeutic strategy capable of addressing schizophrenia-related dysfunction.
Dr. Camilo de la Fuente-Sandoval has developed a groundbreaking approach to schizophrenia treatment prediction using neuroimaging and comprehensive clinical care. His team's research reveals elevated glutamate levels in the associative striatum that normalize with effective antipsychotic treatment.
Researchers at the Institute for Basic Science have discovered that excessive GABA produced by astrocytes impairs fear extinction in PTSD. A new brain-permeable drug called KDS2010 has reversed PTSD-like symptoms in mice, providing a promising therapeutic approach.
Researchers used IntelliCage to assess spontaneous behavioral changes in a mouse model of schizophrenia, finding increased hyperactivity and exploratory behavior after treatment with MK-801. However, cognitive flexibility was impaired, suggesting schizophrenia-like behaviors.
Scientists have designed a nanobody made from llama antibodies to activate a glutamate receptor involved in neural activity, improving cognitive function in mouse models of schizophrenia. Peripheral administration has shown promise as a new therapeutic strategy for treating the condition.
Researchers from Drexel University's A.J. Drexel Autism Institute examined hospitalizations for mental health conditions in autistic adults and found that nearly 1.5 times more autistic adults were readmitted to the hospital within 30 days of initial discharge compared to non-autistic adults.
Dr. Deanna L. Kelly has been named Director of the Maryland Psychiatric Research Center, building on her expertise in schizophrenia treatments and nutrition. She continues to advance personalized treatment options, including effective medications and innovative dietary interventions.
A Nagoya University group created a sandwich ELISA technique to accurately measure polysialic acid levels in the blood of patients with psychiatric disorders. The technique uses antibodies that minimize non-specific binding, resulting in increased accuracy.
A new research paper introduces DoliClock, a biological aging clock based on lipid profiles in the human brain, showing accelerated brain aging in individuals with autism, schizophrenia, and Down syndrome. The study found that dolichol levels serve as reliable biomarkers of aging.
Researchers have developed a once-a-week pill that can be taken orally to deliver medication to patients with schizophrenia. The treatment maintains consistent levels of the drug in the body and controls symptoms, making it easier for patients to adhere to their medication regimen.
The Lieber Institute is developing a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as schizophrenia. The institute is utilizing AWS gen AI and compute services to advance research and store its massive collection of genomic and other data in the cloud.
A new study found that taking antipsychotic medication as prescribed significantly reduces the odds of a motor vehicle crash among drivers with schizophrenia. Researchers analyzed 20 years of data and found a 50% reduction in crash risk among those who adhered to their medication.
A new study published in Neuron has identified a brain region, the fusiform gyrus, as key to distinguishing between real and imagined experiences. The region's strength of activity can predict whether someone judges an experience as real or imagined.
A new study shows that lowering EMC10 levels restores brain function and memory in models of 22q11.2 Deletion Syndrome. Reducing EMC10 activity also alleviates symptoms, including improved cognitive deficits and social memory performance.
A new study finds that Medicaid unwinding disrupted kids' and young adults' access to chronic disease medication, particularly for those living in states with the largest drops in Medicaid enrollment. The disruptions led to increased use of private insurance or cash for prescriptions, exacerbating health issues.
A recent study by the University of Zurich examined the connection between retinal nerve connections and schizophrenia. The researchers found that individuals with a higher genetic risk for schizophrenia tend to have thinner retinas, which can be detected using non-invasive retinal measurements.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.
A nationwide Finnish register-based cohort study found that young people with mental disorders are less likely to become parents compared to those without such diagnoses. The strongest associations were for schizophrenia and depression, with men being 38% less likely to become fathers due to depression diagnosis.
University of California researchers developed a new drug, JRT, with reduced hallucinogenic potential compared to LSD. The compound has shown promise in treating the negative and cognitive symptoms of schizophrenia, including anhedonia and cognitive function.
Researchers have found that puberty triggers significant changes in brain connectivity patterns in individuals with a rare genetic disorder tied to autism. The study suggests that synaptic dysfunction during development may contribute to the condition's behavioral challenges.
Dr. Romina Mizrahi's PET-based neuroimaging sheds light on brain workings, integrating genetics, environment and imaging to understand psychiatric illness as a complex biological puzzle. She advocates for precision psychiatry paradigm with customized treatments based on molecular profiles, and calls for diversity in academic leadership.
The latest APA journal issues explore treatment and risk factors for schizophrenia, as well as medical mistrust and bias. Research also examines the management of borderline personality disorder, including good psychiatric practice and its effectiveness.
Dr. Consuelo Walss-Bass shares her groundbreaking research on schizophrenia, emphasizing the importance of considering both genetic predisposition and environmental factors. She also discusses her work with induced pluripotent stem cells to develop personalized psychiatry and reduce stigma around mental health.
A study by the University of the Basque Country has detected potential biomarkers in the blood that could help predict the risk of developing schizophrenia due to cannabis use. The researchers found significant differences in fatty acid content between cannabis users, individuals with schizophrenia, and those with dual diagnoses.
Research reveals that placental DNA methylation influences expression of genes associated with psychiatric disorders, suggesting genetic risk manifests during prenatal stage. The study identifies schizophrenia, bipolar disorder, and major depression disorder as most strongly linked conditions.
Researchers at WVU have discovered a way to fine-tune zinc activity to improve messaging in the brain, with potential applications for treating conditions such as autism, schizophrenia and Alzheimer's disease. The study identified new compounds that can selectively change synaptic connections by modulating zinc levels.
The March issues of The American Journal of Psychiatry and Psychiatric Services bring together new developments in treating depression, obsessive-compulsive disorder, and schizophrenia. These journal publications highlight the latest advancements in digital mental health innovations.
A new study reveals that schizophrenia's complexity is reflected in the individual brain structures of patients, with some experiencing perceptual disturbances and others cognitive impairments. The research suggests a precision medicine approach could tailor therapies to each patient's unique neurobiological profile.
Research highlights differences in genetic risk of schizophrenia between men and women, with men showing a specific association with positive schizotypy traits. The study suggests that environmental factors may modulate the expression of genetic risk differently in men and women.
Researchers found that empathic disequilibrium, an imbalance between cognitive and emotional empathy, better explains symptoms in various clinical conditions. Prof. Florina Uzefovsky's work suggests this concept can be a powerful diagnostic and treatment tool for autism, schizophrenia, and other disorders.
Researchers from Aarhus University found a machine-learning algorithm that can predict patients with high risk of developing schizophrenia or bipolar disorder within the next five years. The study analyzed electronic health record data and identified key factors, including words describing symptoms in clinical notes.
Researchers discovered a genetic mutation that increases glycine decarboxylase enzyme, linked to schizophrenia behaviors in mice. The study provides a direct genetic link to psychosis and sheds light on the biochemical pathways involved.
Researchers used machine learning to predict diagnostic transition to schizophrenia and bipolar disorder, with schizophrenia being notably easier to forecast. By analyzing routine clinical data, the study suggests a possible approach for early intervention and personalized treatment plans.
Studies identified 153 cases of psychosis caused by brain lesions, which connected to a common circuit in the hippocampus. The circuit, including the rostromedial prefrontal cortex, is a promising target for transcranial magnetic stimulation therapy, potentially improving symptoms in patients with schizophrenia.
A new study published in Brain Medicine reveals that over 26.7% of schizophrenia patients experience distinct manic symptoms, which can be predicted by the severity of positive symptoms such as hallucinations and delusions.
A new study found that the brain's cerebral cortex acts like a memory machine, encoding new experiences and predicting the near future. Novelty detection is a critical function for humans and animals, allowing them to adapt and improve their predictions of future events.
A new study found that cannabis use disorder is increasingly associated with new schizophrenia cases in Ontario, with the proportion rising from 4% to 10%. The trend has tripled over the past 17 years, with heavy cannabis use linked to worsening symptoms and increased risk of psychosis.
Researchers identified a deficit in contrast perception among people with schizophrenia, which affects identifying shapes, textures, and details. Further studies are needed to confirm this relationship and explore the role of medication and other factors.
A cohort study of Medicaid beneficiaries with schizophrenia reveals rapid diffusion of telemedicine care following the COVID-19 pandemic. Within-agency racial and ethnic differences in telemental health care adoption were observed, underscoring the need for monitoring innovation diffusion across vulnerable populations.
Researchers found significant differences in immune cell populations between healthy individuals and people with schizophrenia, with the CD4/CD8 ratio emerging as a potential biomarker for predicting treatment response. Lower levels of mucosal-associated invariant T cells may signify immune dysregulation in schizophrenia.
A recent study has identified distinct features in two types of brain cells, intratelencephalic (IT) neurons and pyramidal tract (PT) neurons, which may affect their vulnerability to neurodevelopmental conditions. The research highlights the importance of understanding how these brain cells exchange information through their synapses.
Dr. Carrie Bearden's groundbreaking work combines genetic and brain development insights to identify early warning signs of psychosis in adolescents. Her research has exciting implications for personalized medicine and targeted preventive treatments.
Emory University MD candidate Fayzan Rab's research investigates the economic and public health implications of psychedelic therapy implementation. His work emphasizes making these innovative treatments accessible to traditionally underserved communities.
A new study has identified a specific connectivity pattern of brain atrophy in schizophrenia, distinct from brain networks associated with other psychiatric disorders. The findings suggest that this network may be a core characteristic of schizophrenia and could inform treatment plans.
A new study by the University of Waterloo found that nearly 68% of Canadian patients who used antipsychotics had more behavioral issues than before medication. Non-drug therapies like music and social interaction have been shown to help manage behavior without antipsychotics.
Scientists at St. Jude Children's Research Hospital found a link between the chromosomal disorder 22q11.2 deletion syndrome and schizophrenia, with malformations in the cerebellum causing Tbx1 gene loss leading to improper skull formation.
Research from King's College London finds that frequent cannabis use increases psychosis risk, regardless of genetic load for schizophrenia. The study used polygenic risk scores to investigate the relationship between cannabis use and psychosis.
A UT Health San Antonio study found that brain volume changes correlate with social behavior differences in psychiatric conditions such as autism spectrum disorder and schizophrenia. Tbx1 deficiency was associated with decreased brain volume in the amygdala and surrounding cortical regions, affecting desire for social interaction.
Researchers identified iTBS over the left dorsolateral prefrontal cortex as the most effective method for treating adults with schizophrenia, improving negative and cognitive symptoms. The treatment approach was well-accepted and well-tolerated by participants.
Research by Prof. Falkai suggests promising new directions in schizophrenia treatment through brain plasticity and myelin regeneration. His work challenges traditional views of the disorder and opens new therapeutic possibilities, particularly when combining aerobic exercise with a repurposed drug.
Researchers at the University of Rochester Medical Center have discovered a potential biomarker for psychosis diagnosis by analyzing brain connectivity patterns. The 'somato-visual' biomarker shows promise in predicting psychosis onset and stratifying patients into clinically meaningful subgroups.
A new study found that cannabis use worsens reduced brain connectivity in individuals at high risk of psychosis. This deficit is associated with symptoms like social withdrawal and lack of motivation, which are difficult to treat with current medications.
A study by Florida Atlantic University found that virtual reality training increased empathy and sympathy towards individuals with mental health conditions in police officers. The training, which simulated realistic scenarios, allowed officers to practice handling complex civilian interactions with greater emotional connection.
A new study found that fampridine can improve working memory in individuals with reduced cognitive function, particularly those with low baseline working memory levels. The drug increased brain excitability and enabled faster processing of stimuli.
A new study found that individuals with hallucinogen-related emergency department visits are at a high risk of developing schizophrenia. The study analyzed health data for over 9.2 million individuals in Ontario, Canada, and found a 21-fold increased risk of schizophrenia compared to the general population.
Researchers at Tufts University and Vanderbilt University developed a biomarker to detect inflexible thinking in schizophrenia. The study found that people with schizophrenia generate unique neural patterns when making decisions based on conflicting information.
Researchers discovered brain cells that map an animal's position in behavioural coordinates, helping understand how the brain generates complex behaviors. The findings may be useful in understanding psychiatric conditions such as schizophrenia.
Researchers developed a method to visualize AMPA receptors using PET scans, revealing differences in density and distribution between healthy subjects and those with psychiatric disorders. This discovery may lead to new diagnostic and therapeutic approaches for conditions like schizophrenia, bipolar disorder, and autism spectrum disorder.